NRX Pharmaceuticals (NRXP) Non Operating Interest Expenses (2020 - 2026)

NRX Pharmaceuticals (NRXP) has reported Non Operating Interest Expenses for 7 consecutive years, with $240000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $240000.0 in Q2 2026; TTM through Jun 2026 was $1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $671000.0, down 9.45% from the prior year.
• Non Operating Interest Expenses was $240000.0 for Q2 2026 at NRX Pharmaceuticals, up from $233000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $671000.0 in Q4 2025 and troughed at $3000.0 in Q1 2022.
• A 5-year average of $213857.1 and a median of $230000.0 in 2024 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 40.0% in 2022, down 40.0% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at $3000.0 in 2022, then jumped by 2566.67% to $80000.0 in 2023, then surged by 187.5% to $230000.0 in 2024, then surged by 191.74% to $671000.0 in 2025, then tumbled by 64.23% to $240000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $240000.0 (Q2 2026), $233000.0 (Q1 2026), and $671000.0 (Q4 2025), per Business Quant data.